Avalyn Pharma Inc. (AVLN)
AVLNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$29.79
-0.4900 (-1.62%) today
Regular session, Nov 16, 10:46 AM ET
- Market cap
- $1.33bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $29.15 to $30.43
- 52-week range
- $22.24 to $40.17
- Average volume
- –
- Previous close
- $30.28
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $56.50, +89.7% from here
Earnings
next estimate $-0.6700Next report
Mar 2026
-33.3%
Jun 2026
+4.8%
Sep 2026
-4.7%
estimate reported, and the surprise
News
8 latest- Add Up The Pieces: IHE Could Be Worth $116BNK Invest · Sep 28, 2026
- Avalyn Publishes Phase 1 Data Supporting Lung-Targeted AP02 In Lung Disease RTTNews · Sep 22, 2026
- Avalyn Pharma Adds Former FDA Executive To Board As AP01, AP02 Trials Progress RTTNews · Sep 17, 2026
- Avalyn's AP01 Shows Broad Lung Distribution In ERS 2026 In-Silico Modeling Data RTTNews · Sep 9, 2026
- Avalyn Advances Inhaled Fibrosis Therapies; MIST Phase 2b Enrollment Completed RTTNews · Aug 12, 2026
- Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE RTTNews · Aug 10, 2026
- Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data AheadMarketBeat · Jun 5, 2026
- Monday 5/4 Insider Buying Report: AVLN, CSGPBNK Invest · May 4, 2026
The company
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The Company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn's AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn's AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- avalynpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.